| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| SMS | | | | | | | | 15.3 |
| Apothecary Rx | | | | | | | | 81.3 |
| Total revenues [+] | 126.1 | 101.9 | 87.2 | 53.0 | 17.5 | 20.5 | 17.6 | 96.6 |
| Products | | | | | 5.0 | 5.6 | | |
| Services | | | | | 12.6 | 15.0 | | |
| Healthcare | 236.0 | 187.3 | 158.5 | 38.2 | | | | |
| Management fees | 5.4 | 5.4 | 6.3 | 7.9 | | | | |
| Other | 5.9 | 5.4 | 3.5 | 0.8 | | | | |
| Revenue growth | 23.8% | 16.8% | 64.6% | 202.5% | -14.7% | 16.8% | -81.8% | 92.0% |
| Cost of goods sold [+] | 33.9 | 29.3 | 28.3 | 15.7 | 6.9 | 7.1 | 5.5 | 67.8 |
| Cost of product sales | | | | | 1.7 | 1.6 | | |
| Cost of services | | | | | 5.1 | 5.5 | | |
| Other cost of sales | 53.9 | 42.8 | 32.8 | 18.5 | | | | |
| Supplies costs | 27.8 | 24.0 | 22.9 | 11.1 | | | | |
| Gross profit | 92.3 | 72.6 | 58.9 | 37.3 | 10.6 | 13.4 | 12.0 | 28.8 |
| Gross margin | 73.1% | 71.3% | 67.6% | 70.4% | 60.7% | 65.2% | 68.6% | 29.8% |
| Selling, general and administrative [+] | 27.8 | 24.0 | 22.9 | 11.1 | 13.7 | 15.8 | 13.6 | 23.8 |
| General and administrative | 27.8 | 24.0 | 22.9 | 11.1 | | | | |
| Equity in earnings | 1.4 | 2.4 | 5.9 | | | | | |
| Other operating expenses | 53.9 | 42.8 | 23.4 | 18.8 | 0.9 | 9.9 | 4.8 | |
| EBITDA [+] | 12.0 | 8.2 | 18.5 | 7.4 | -4.0 | -12.3 | -5.3 | 2.1 |
| EBITDA growth | 46.0% | -55.9% | 151.9% | -283.5% | -67.5% | 131.9% | -350.0% | -43.2% |
| EBITDA margin | 9.5% | 8.0% | 21.3% | 13.9% | -22.9% | -60.0% | -30.2% | 2.2% |
| Depreciation | 3.6 | 3.5 | 3.2 | 1.8 | 1.0 | 1.3 | 1.1 | 1.6 |
| EBITA | 8.3 | 4.7 | 15.3 | 5.5 | -5.0 | -13.6 | -6.4 | 0.6 |
| EBITA margin | 6.6% | 4.6% | 17.6% | 10.5% | -28.4% | -66.3% | -36.4% | 0.6% |
| Amortization of intangibles | 2.1 | 2.1 | 1.9 | 0.8 | 0.1 | | | |
| EBIT [+] | 6.3 | 2.6 | 13.4 | 4.8 | -5.1 | -13.6 | -6.4 | 0.6 |
| EBIT growth | 137.3% | -80.4% | 182.2% | -193.1% | -62.3% | 112.9% | -1253.4% | -81.1% |
| EBIT margin | 5.0% | 2.6% | 15.4% | 9.0% | -29.2% | -66.3% | -36.4% | 0.6% |
| Non-recurring items [+] | | | 21.9 | | | 0.8 | | |
| Asset impairment | | | 21.9 | | | 0.8 | | |
| Interest expense, net [+] | 1.1 | 1.6 | 2.2 | 1.3 | 1.3 | 1.2 | 0.9 | -1.2 |
| Interest expense | 1.1 | 1.6 | 2.2 | 1.3 | 1.3 | 1.2 | 0.9 | |
| Interest income | | | | | | | | 1.2 |
| Other income (expense), net [+] | 0.0 | 0.4 | 0.1 | 0.3 | 0.0 | 0.0 | 0.0 | -0.4 |
| Impairment of investments | | | 1.6 | 0.2 | | | | |
| Deferred gain on sale of assets | | | 4.0 | | | | | |
| Other | 0.0 | 0.4 | 0.1 | 0.3 | 0.0 | 0.0 | | |
| Pre-tax income | 5.2 | 1.4 | -10.4 | 3.8 | -6.4 | -15.6 | -7.3 | 1.4 |
| Income taxes | -1.1 | -0.9 | 3.8 | 0.0 | 0.0 | 0.1 | 0.0 | -0.1 |
| Tax rate | | | | 1.2% | | | 0.0% | |
| Minority interest | 6.6 | 3.8 | 4.3 | 0.0 | -0.2 | -0.2 | -0.2 | 0.6 |
| Earnings from continuing ops | -1.0 | -2.3 | -19.6 | 2.5 | -12.6 | -15.6 | -7.3 | 0.7 |
| Earnings from discontinued ops | 6.2 | 0.3 | -0.8 | | 0.3 | -3.6 | -5.2 | 0.1 |
| Net income | 5.2 | -2.1 | -20.4 | 2.5 | -12.3 | -19.1 | -5.3 | 0.7 |
| Net margin | 4.1% | -2.1% | -23.4% | 4.6% | -70.3% | -93.2% | -30.4% | 0.8% |
| |
| Basic EPS [+] | ($0.06) | ($0.14) | ($1.44) | $0.02 | ($1.09) | ($2.15) | ($0.26) | $0.03 |
| Growth | -57.8% | -90.4% | -9614.1% | -101.4% | -49.1% | 730.8% | -998.3% | 117.1% |
| Diluted EPS [+] | ($0.06) | ($0.14) | ($1.44) | $0.02 | ($1.09) | ($2.15) | ($0.26) | $0.03 |
| Growth | -57.8% | -90.4% | -9614.1% | -101.4% | -49.1% | 730.8% | -1005.9% | 115.3% |
| |
| Shares outstanding (basic) [+] | 17.3 | 17.1 | 13.6 | 162.5 | 11.5 | 7.2 | 28.4 | 25.9 |
| Growth | 1.1% | 25.3% | -91.6% | 1310.0% | 59.0% | -74.5% | 9.8% | 26.9% |
| Shares outstanding (diluted) [+] | 17.3 | 17.1 | 13.6 | 162.5 | 11.5 | 7.2 | 28.4 | 26.1 |
| Growth | 1.1% | 25.3% | -91.6% | 1310.0% | 59.0% | -74.5% | 8.9% | 27.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |